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CONSPECTUS   
The cell membrane, the gastrointestinal tract or the blood-brain barrier 
(BBB) are good examples of biological barriers that define and protect cells 
and organs. They impose different level of restrictions but they also share 
common features. For instance, they all display a high lipophilic character. 
For this reason, hydrophilic compounds, like peptides, proteins or nucleic 
acids have long been considered as unable to bypass them. However, the 
discovery of cell-penetrating peptides (CPPs), opened a vast field of 
research. Nowadays, CPPs, homing peptides and blood-brain barrier 
peptide shuttles (BBB-shuttles) are good examples of peptides able to 
target and/or to cross various biological barriers. 
CPPs are a group of peptides able to interact with the plasma 
membrane and enter the cell. The display some common characteristics like 
positive charged residues, mainly arginines, and amphipathicity. In this 
field, our group has been focused on the development of proline rich CPPs 
and in the analysis of the importance of secondary amphipathicity in the 
internalization process. Proline has a privileged structure being the only 
aminoacid with a secondary amine and a cyclic side chain. These features 
constrain its structure and hamper the formation of H-bond. Taking advantage of this privileged structure, three different families of 
proline-rich peptides have been developed, namely, proline-rich dendrimer, sweet arrow peptide (SAP) and a group of foldamers 
based on γ-peptides. The structure and the mechanism of internalization of all of them has been evaluated and analyzed. 
BBB-shuttles are peptides able to cross the BBB and to carry with them compounds that cannot reach the brain parenchyma 
unaided. These peptides take advantage of the natural transport mechanisms present at the BBB, which are divided in active and 
passive transport mechanisms. On the one hand, we have developed BBB-shuttles that cross the BBB by passive transport 
mechanism, like diketoperazines (DKPs), (N-MePhe)n or (PhPro)n. On the other hand, we have investigated BBB-shuttles that 
utilizes active transport mechanism such as SGV, THRre or MiniAp-4. For the development of both groups we have explored 
several approaches, such as the use of peptide libraries, both chemical and from phage display, or hit-to-lead optimization processes.  
In this article, we describe, by chronologic order, our contribution to the development of peptides able to overcome various 
biological barriers and our efforts in order to understand the mechanism that they display. In addition, the potential use of both, CPP 
and BBB-shuttles, to improve the transport of promising therapeutic compounds is described. 
 
Introduction 
Delivery of bioactive compounds through various biological barriers has been a 
challenge for a long period of time. The plasma membrane, the gastrointestinal barrier 
or the blood-brain barrier (BBB) are examples of biological hurdles that limit the access 
of therapeutics to the desired target. The simplest of them, the cellular membrane, has 
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being traditionally considered impermeable to hydrophilic compounds since only 
lipophilic compounds were able to interact with the lipid bilayer. Thus, delivery of 
peptides, proteins or nucleic acids to the cytoplasm was considered a utopia thirty years 
ago. However, the discovery of penetratin and TAT peptides, based on natural proteins, 
opened a vast field of research.1,2 This new family of compounds, named cell-
penetrating peptides (CPPs) accounts nowadays for more than 100 members, with 
various origins.3 During its development several challenges have been addressed, such 
as endosomal entrapment upon internalization4 or protease liability.5 To date, CPPs 
have been used to deliver several cargoes into the cell, such as nanoparticles of various 
types, nucleic acids or proteins.6  
Intracellular targets are now readily accessible by using CPPs but there are other 
biological barriers that preclude the access of drugs to their target. For instance, oral 
delivery is hampered by the gastrointestinal barrier.7 More difficult to overcome is the 
BBB that limits the access of 98% of drugs to the brain while completely preventing the 
passage of macromolecules.8 In both cases, several peptides have been described to 
interact with some of the components of these barriers with the aim to overcome them.9-
11  
During this process of evolution our group have played an active role in the 
development and study of CPPs, first, and then brain delivery vectors. The purpose of 
this Account is to give an overview on peptides able to overcome biological barriers 
with a special focus on recent work from our group. 
 
Proline rich cell-penetrating peptides  
CPPs can be classified according to various parameters, such as sequence or 
internalization mechanism, to name a few.3 The latter is affected by several factors, such 
as net charge or structure. For instance, amphipathicity, imposed by the sequence of the 
peptide, and secondary amphipathicity, determined by peptide secondary structure, are 
key for internalization. Amphipathic alpha helixes, defined by having two separated 
hydrophobic and hydrophilic faces, are a shared structural motif in a wide variety of 
CPPs.12 
Proline is one of the 20 genetically encoded amino acids but the only one with a 
secondary amine and a cyclic side chain which constrain its structure. Moreover, the 
amino group of proline cannot participate in H-bond, unlike in the other natural amino 
acids. These characteristics confer unique structural properties to polyproline peptides 
which adopt well defined conformations that vary depending on the environment 
(Figure 1A). In organic solvents, polyproline adopts a polyproline I (PPI) conformation, 
which is characterized by being a right handed cis orientated helix with 1.9 residues per 
turn. In aqueous solutions, polyproline adopts a PPII conformation, meaning a left 
handed helix, trans oriented and with 3.0 residues per turn.13 These particular secondary 
structures inspired us to design a drug delivery system consisting of proline based 
dendrimers (Figure 1D).14 Peptide based dendrimers are unique compounds.15 They can 
be seen as globular proteins and among all the potential applications, their branched 
structure can facilitate drug entrapment. We proposed that this property would be 
stressed in our system due to the plasticity conferred by the polyproline sequence. The 
dendrimer was prepared using cis-4 amino-L-proline as the scaffold (Figure 1C).16,17 
The second amino group was used as a branch point. Extensive conformational analysis 
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proved the transition from a compacted PPI structure to a more extended PPII 
conformation as well as the contrary. The antibiotic ciprofloxacin was successfully 
encapsulated. The potential of this system was further analysed by evaluating its 
internalization properties. Interestingly, the prepared dendrimer internalized in rat 
kidney cells but, surprisingly, the control peptide (P14) did as well.
14 This result, 
together with our experience with γ-zein protein, led us to study the internalization 
capabilities of (VXLPPP)n peptides. The amphipathic secondary structure but non 
amphipathic sequence make these peptides very facinating. We prepared a library of 
(VXLPPP)n (X= H, K, R; n= 1,2,3) and compared to Pm (m= 6,12,18). The peptide with 
better internalization properties on HeLa was (VRLPPP)3 (Figure 1B).
18 Remarkably, 
when compared with TAT and penetratin, the new designed vectors displayed no 
toxicity despite of the internalization differences. The interesting internalization 
properties of (VRLPPP)3, named the sweet arrow peptide (SAP), have been enhanced 
by introducing fatty acid moieties on its sequence19 or by mutating one of the proline 
residues to silaproline.20 Noteworthy, none of the aforementioned SAP versions 
displayed cytotoxicity that combined with the non-viral origin and high solubility of 
these compounds make them very interesting CPPs. 
CPP internalization mechanism has generated some debate in the scientific 
community.21 Discussion around the existence or not of an endocytic pathway has 
promoted several studies. In this context, we analysed the internalization mechanism of 
SAP finding evidence of lipid raft mediated mechanism.22 Analysis of the intracellular 
pathway followed by SAP combined with the stability in front of proteases suggested 
endosomal release of the peptide to the cytoplasm rather than degradation.  
Liability to proteases is one of the main drawbacks of using peptides as therapeutics and 
it can be consider as another biological barrier to overcome. Among the several 
strategies that can be applied to enhance this stability the use of D-amino acids stands 
out. SAP has good stability versus proteases but for further applications we explored the 
synthesis of a fully protease resistant version by preparing the peptide with D-amino 
acids (Figure 1B).23 (vrlppp)3 was shown to be remarkably more stable than its 
counterpart, both in serum and in front of trypsin. Remarkably, analysis of the 
internalization mechanism showed that both versions behaved similarly suggesting that 
the internalization process was receptor independent since the stereochemistry of the α-
carbon does not affect. Further analysis, by circular dichroism (CD) showed that both 
peptides had a PPII structure but inverted. The peptide kept the propensity to form 
fibrillary aggregates, demonstrating that neither the inversion of all the α-carbon 
stereogenic centers nor the consequent change in helix handedness affect to the overall 
topology of the aggregate. Importantly, the new version, preserved the same CPP 
properties than its L-counterpart. Heparin competition assays showed minor impact in 
internalization ruling out electrostatic interactions with the glycocalix as a main 
internalization trigger. Further studies confirmed an active internalization pathway. 
Again, lipid raft/caveolae was seen as the most plausible internalization mechanism. 
Preliminary studies in mice proved the suitability of D-SAP for in vivo applications.24  
Taking into account the lack of inhibition of the internalization of SAP by heparin and 
in order of fully validate the importance of the PPII configuration in the internalization 
process, a negative version of SAP, SAP(E), was prepared, by mutating arginine to 
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glutamic acid (Figure 1B).25 The internalization mechanism of this new peptide was 
confirmed as the same for SAP, opening the venue for delivering more challenging 
cargoes. Most of the CPP described to date are either cationic or amphipathic, being 
optimal for complexation with DNA and other negatively charged molecules. A 
negative charged CPP would allow for complexation to yet unexplored cargoes with 
positive net charge.  Interestingly, both SAP and SAP(E) have been recently used to 
deliver SiC-NP to cells.26  
All these results suggest that internalization of SAP and SAP(E) may be triggered or 
affected by its self-assembly.27 Recent analyses of the interaction of SAP(E) with lipids, 
as a model of the cytoplasmic membrane, demonstrate that only interaction with the 
polar head groups occur and no membrane insertion is observed.28 
Our interest in proline based structures lead us to develop a new family of CPPs 
consisting on γ-peptides, using cis-4-amino-L-proline as a scaffold. In this family of 
foldamers, the peptide amide bond was formed at the amino group at position 4, and the 
α-amino group was used to introduce different groups, both acyl and alkyl chains 
(Figure 1E). Exhaustive analysis by both NMR and CD allowed for the identification of 
secondary structures suggesting the formation of isolated H-bond ribbon, identifying the 
smallest β-strand.29 Evaluation of the internalization mechanism of a selection of these 
peptides suggested an endocytic pathway. This family of peptides displays improved 
solubility, low cytotoxicity, remarkably stability versus proteases and good 
internalization properties.30 
Brain targeting peptide BBB-shuttles 
CPPs enter the cell by a not yet completely understood mechanism. What is clear is that 
tissue selectivity is not always achieved. Some peptides, known as homing peptides, are 
designed to recognize specific tissues.31 However, in the case of the brain, this selective 
transport is even more difficult to get due to the presence of the BBB. The BBB is a 
physiological and metabolic barrier resulting from a complex interaction between 
endothelial cells and several cells types, like pericytes or end foot astrocytes present at 
the brain. The main function of the BBB is to protect the brain limiting the entrance of 
unwanted substances. Several restrictions like low vesicular transport, the presence of 
tight junctions, a high proteolytic activity or the presence of efflux pumps limit the 
access of exogenous substances to the brain. These features make delivery of 
therapeutics difficult. An early work in 1999, showed that a 120 kDa enzyme 
conjugated to TAT was delivered in its active form into the brain.32 Despite of the lack 
of brain selectivity, this seminal study paved the way for peptide mediated brain 
delivery. Initial studies evaluated some of the most promising CPPs as brain delivery 
vectors. Although brain penetration was accomplished in some cases, selectivity was a 
major problem. Moreover, poor analysis methods make difficult to distinguish among 
parenchyma distribution of the peptide and entrapment in the brain capillaries.10 A 
recent study has demonstrated that CPPs can enter the brain but their efflux rate is 
greater than their influx one, limiting its use as brain delivery vectors.33  
The brain has high energy requirements having several transport mechanisms that could 
be ideally exploited for brain delivery. For instance, small molecules like glucose or 
amino acids have specific transporters and proteins like transferrin or insulin have 
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specific receptors. Additionally, unspecific transport mechanisms can be observed as 
well, such us passive diffusion or adsorptive-mediated transcytosis. The various 
transport mechanisms can be classified into passive or active.10  
Passive crossing 
Numerous strategies have been developed to improve brain uptake of therapeutics.34 
Among them, we have focused on the development of specific peptide brain delivery 
vectors, named BBB-shuttles.10 One of the first approaches that we explored consisted 
on design of BBB-shuttles by using a genetic algorithm which optimized the physico-
chemical properties of the peptides in order to increase their passive transport.35 The 
optimization process consisted in reduction of hydrogen bonding units on the peptide, 
fine tuning of the logP and increase of lipophilicity, among others. It yielded a set of 
peptides with several N-methylations that complicated the synthesis of the library.36 
Analysis of the library led to the discovery of two candidates to BBB-shuttle 
highlighting the potential of genetic algorithms to generate new brain delivery vectors.37  
During the preparation of the previous library, diketopiperazine (DKP) formation was 
observed (Figure 2A). Interestingly, one of the subproducts, DKP N-MePhe-N-MePhe, 
had very good transport through the tested methods. This result motivated us to prepare 
two libraries of DKPs, mono and di-N-methylated in order to assess if the second 
methyl group improved the transport or increased membrane retention. This was the 
case for the highly hydrophobic DKPs, whilst most of them showed higher 
permeability. Moreover, two relevant cargoes were evaluated, baicalin, a flavonoid that 
inhibits prolyloligopeptidase (POP), and L-DOPA, a precursor of dopamine, improving 
the in both cases, the permeability of the cargo. In the case of baicalin, its POP 
inhibitory activity was also preserved.38 The application of DKPs was further explored 
in the design of chemical delivery systems which consisted of brain permeable 
compounds that would undergo chemical transformation once in the brain parenchyma 
(Figure 2A’). This transformation would trap the compound inside the brain leading to a 
sustained delivery of the compound of interest. Introduction of N-
methyldihydropyridine moiety to the DKP scaffold conferred the desired reactivity to 
the systems. This system has been validated for L-DOPA.39 Evaluation of both, 
permeability through the BBB, by means of parallel artificial membrane permeability 
assay (PAMPA), and POP inhibition confirmed our hypothesis.40 DKPs have recently 
been evalutated in vivo41 and for dermal delivery of small drugs.42 
The use of peptide libraries is a very attractive tool to discover new hits with a given 
activity. We have used several types of libraries to find shuttles targeting BBB transport 
mechanism. For instance, considering the potential of passive diffusion shuttles to 
increase the brain uptake of small polar drugs, we have investigated various libraries of 
peptides designed to passively cross the BBB.43-46 Molecular weight, lipophilicity and 
hydrogen bonding are the key parameters to study. Based on our experience on the use 
of N-methyl amino acids36 we selected this feature as key parameter of some of the 
libraries created. In a first work, N-methylphenylalanine (N-MePhe) (Figure 2B), a 
fairly common amino acid in nature, was selected as a monomer to create a library of 
potential BBB-shuttles.47 First, the length of the peptides was adjusted with 4 amino 
acids being the optimal length.46 Then, the C and N terminus were optimized to acetyl 
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and amide group, respectively. At this point, the fourth amino acid was mutated. The 
peptides with N-MePhe, cyclohexylalanine (Cha), and 2-naphtylalanine (2Nal) had the 
higher transport. These 3 peptides were selected to transport L-DOPA, enhancing its 
permeability. Noteworthy, all the peptides have remarkable stability in front of serum 
proteases. Later, the applicability of these shuttles was expanded to other cargoes.45 
Comparison to a library of proline based peptides pointed to the phenyl group as 
responsible for the privileged transport.46 
Although the concept of an universal shuttle is very attractive, several studies indicate 
that the right approach contemplates a one shuttle-one cargo strategy.10 Knowledge 
about the key parameters that influence BBB transport can help to fine tune a given 
shuttle. Exploiting this theory we have evaluated several parameters to create BBB-
shuttles at will.44 The first parameter to evaluate was the chirality. Based on N-MePhe, a 
library of 16 BBB-shuttles was prepared, combining all diastereoisomers. PAMPA and 
artificial membrane chromatography (IAMC) were used as evaluation tools. Various 
conclusions were extracted. First, homochiral peptides (DDDD or LLLL) showed less 
lipophilicity and higher permeability. Second, when increasing the lipophilicity, the 
membrane retention was higher resulting in a diminution of the permeability. Third, 
enantiomeric discrimination was observed. With these results in hand, we explored if 
the permeability of a cargo can be fine-tuned by modifying the selected shuttle. With 
this aim, three different cargoes were compared (Figure 2c). For two of them, the 
tetramer gave better results while for one the trimer was the most efficient. With this 
result an a la carte shuttle is described (Figure 2C). After, other parameters such as non-
natural amino acid incorporation and halogenation were analysed. In all cases, cargo-
based differences were found. Several factors such as peptide shuttle length, 
stereochemistry or halogen content can be fine-tuned to fully optimize the transport of 
the drug of interest.44  
Despite of the promising features of the described BBB-shuttles, their reduced water 
solubility (<1µM) can hamper its use. With the aim of developing water soluble shuttles 
we decided to prepare a library of potential shuttles by combining the characteristics of 
N-MePhe and polyproline peptides, by preparing polyphenylproline peptides. Proline 
has a restricted conformation due to its cyclic side chain and high solubility in water. 
Moreover, the phenyl group has been reported to have a positive impact on membrane 
penetration.25 To merge the advantages of both amino acids, cis-3-phenylpyrrolidine-2-
carboxilic acid (PhPro) (Figure 2B) was used as scaffold. When comparing the 
diastereomeric mixture of (N-MePhe)4 to (PhPro)4, a similar transport profile was 
observed by PAMPA. Moreover, the transport of two cargoes further demonstrated the 
shuttle capability of this new family of compounds. Noteworthy, the water solubility 
was increased 1000-fold. In two pairs of enantiomers was enantiomeric discrimination 
observed. These peptides, displayed a complete different structure from the one of the 
parent peptides (Pro4 and N-MePhe4) suggesting the new secondary structure as main 
reason of the discrimination observed at the membrane. This work provides a new 
parameter, enantiomeric discrimination, to evaluate when designing peptides to cross 
biological membranes by passive diffusion mechanism.43  
Active crossing 
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Among the several transport mechanism available at the BBB, active transport 
mechanism offers several advantages. By targeting specific receptors, the delivery to 
peripheral tissues will be reduced. Additionally, it allows for the transport of a wider 
range of compounds that can vary in size, charge and nature.  
In order to discover new BBB-shuttles that target an active transport mechanism, a 
phage display (PD) peptide library was confronted to an in vitro human cell-based BBB 
model (Figure 3),48 leading to the discovery of SGV. The transport of this peptide was 
corroborated in the same assay obtaining permeability values similar to previous 
described shuttles.49,50 This work validated the use of PD against human cell-based 
models of the BBB as a valuable strategy to discover new BBB-shuttles.  
The main limitation of PD techniques is that the peptides obtained are formed by natural 
amino acids, thus being labile to proteases. To solve this problem, we have generated 
peptide libraries using non-natural amino acids. For instance, we designed a chemical 
library using one-bead-one-compound strategy. For that, a selection of 6 D versions of 
natural amino acids that covered the chemical space and a mix-and-split technique were 
used to generate a library of fully protease resistant heptapeptides,51  ensuring the 
preparation of a highly heterogeneous library. The selection of the amino acids was 
done after careful analysis considering several parameters such as the preference of the 
amino acid to participate in protein-protein interaction or the pKa at physiological pH, 
to name a few. Combination with in vitro models, that mimicked the BBB, and state-of-
the-art mass spectrometry led to the discovery of new BBB-shuttles. The first step was 
the validation of the quality of the library. Then, two BBB models were used to extract 
the sequence of interest. An in vitro cell-based model was used in combination with 
PAMPA to discriminate among active and passive transported shuttles. This process 
was followed by two levels of exhaustive MS analysis, to identify the peptide family 
and the specific peptide. In this article, a stimulating way of obtaining active 
compounds by combining combinatorial chemistry with advanced, but available, MS 
analysis was described.  
Within this last section, we have described our efforts in the discovery of new BBB-
shuttles, mainly by using libraries, both chemical and based on PD. However, other 
strategies have been explored as sources of BBB-shuttles. Two last examples of active 
transported BBB-shuttle have been discovered by hit-to-lead optimizations of given 
BBB-shuttle candidates.49,50  
The first example is THRre,49 a peptide fully resistant to proteases discovered by 
applying the retro-enantio approach to THR.52 THR was discovered by PD against the 
human transferrin receptor (hTfR).53 This receptor is highly expressed at the BBB and 
could be envisaged as a gate of entrance for therapeutics. To test this hypothesis we 
prepared gold nanoparticles (AuNP) modified with THR and CLPFFD, an anti-amyloid 
peptide. Increase in BBB transport of THR modified AuNP was observed both in vitro 
and in vivo. However, the most important finding was the detection of modified 
nanoparticles at various sections of the mouse brain parenchyma, unequivocally proving 
BBB passage of the AuNP system (Figure 4A).52 Up to 0.16 ± 0.11 µg of gold/brain 
(dry tissue) which correspond to a 0.0765 % of the injected dose was found. This 
discovery lead us to further improve the properties of THR. THRre maintain some of 
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the topological features of THR, since it was prepared by reversing the amino acid 
sequence and changing the stereochemistry of the side chains. Several internalization 
studies confirmed TfR as the entry mechanism and showed no competition with 
transferrin. THRre was shown to transport a wide variety of cargoes. Interestingly, in 
vivo two-photon microscopy proved the delivery of THRre modified QDs to the brain 
parenchyma (Figure 4B). We are currently analysing the potential of this peptide. 
The second example of hit-to-lead optimization process is MiniAp-4.50 This time, we 
were inspired by the exquisite composition of venoms. Venoms are rich in peptides with 
important activity at very low doses. We hypothesised that venoms can be a source of 
BBB-shuttles if their toxicity would be reduced, since some of them affect the central 
nervous system (CNS). As a proof-of-concept, we studied apamin, the main component 
of bee venom that has been reported to have CNS activity.54 Luckily, the residues 
involved in toxicity are known and preliminary studies showed that point mutations 
were sufficient to reduce the toxicity of the peptide (Figure 5A and B). By using an in 
vitro cell-based model we evaluated the transport of both peptides, apamin and its non-
toxic analog, ApOO, finding evidence of an active transport mechanism. By this study, 
we suggest the use of modified versions of apamin as BBB-shuttles and point out 
venoms as its sources.34  
Both Apamin and ApOO have promising characteristics as BBB-shuttles. However, 
their immunogenicity, together with the complex synthesis, hamper their use. In order to 
reduce the immunogenicity and the toxicity of these peptides while preserving the brain 
targeting capacity, various minimized versions of apamin were prepared. For the design, 
we selected the part of the sequence not involved in the toxicity, namely, the loop 
between cysteine 3 and 11. In order to preserve the protease stability, a non-natural 
linkage, lactam, was suggested as disulphide bridge surrogate (Figure 5C). The resulting 
macrocycle had improved transport in cell-based BBB model when compared to apamin 
(Figure 6).50 Additionally, its ability to transport a wide variety of cargoes, from 
metallic nanoparticles to proteins, across endothelial cell monolayers, was validated. 
More importantly, we proved that the immunogenic and toxic properties of the apamin 
were abolished.  
Conclusions 
The potential of peptides in biomedicine applies to all the areas, from diagnostics to 
treatment. Peptides can modulate protein-protein interactions,55 can be used as targeting 
moieties, etc. During the last 30 years, drug delivery has been one of the fields where 
peptides have caused a high impact, as proved by the development of CPPs, homing 
peptides and BBB-shuttles, amongst others.9,10,21,31,56 Some of this new vectors have 
even reached clinical trials.57 Our contribution to the field has been focused on the 
search on protease resistant peptides. The introduction of key features like N-
methylation, D-amino acids or cyclisation, help us to modulate interactions of interest 
by reducing the number of H-bonds, the lipophilicity of the compounds or by fixing the 
conformation of the peptides.  
Better knowledge of the composition of the various biological barriers will lead to an 
improved design of peptides able to overcome them. To get to this point, a synergistic 
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approach, which combines receptor analysis and membrane composition, with screening 
of targeted libraries may be needed.  
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Figure 1. A) Structure of PPI and PPII; B) Structure of SAP, SAP(E) and D-SAP; C) cis-4-amino-L-proline; D) 
Core of polyproline dendrimer; E) γ-peptides based on cis-4-amino-L-proline.  
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Figure 2. A) DKP with A’) DKP-POP inhibitor; B) N-MePhe and PhPro; C) Example of a la carte shuttles for L-
DOPA, levulinic and nipecotic acid, respectively.  
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Figure 3. Schematic representation of the process of discovery of SGV: biopanning of a PD library against a 
human BBB cell-based model followed by in vitro evaluation of the selected sequence.  
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Figure 4. A) Schematic representation of AuNP modified with THR. B) TEM micrographs of mice brains 
injected with AuNP-THR.52 Arrows point to AuNP. C) Schematic representation of QDs modified with THRre. 
D) Intravital two-photon microscopy images of the brains of mice after injection of QDs-THRre (in red) 
capillaries are stained in green by FITC-dextran.  
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Figure 5. Apamine derived peptides. A) Apamin. B) ApOO C) MiniAp-4. Common residues of Apamine and 
MiniAp-4 are highlighted in green. Mutated residues from Apamin to ApOO are highlighted in blue.  
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Figure 6. A) Increase in transport of MiniAp-4 modified cargoes in a human-cell-based BBB model. B) 
Fluorescence intensity of the brain region measured in vivo. C) Fluorescence intensity of various organs ex 
vivo. D) Representative confocal microscopy images of brain slices (cortex) of mice injected with Cy5.5–
MiniAp-4 (top) and control (bottom). The Cy5.5 conjugates are shown in green, capillaries in red, and cell 
nuclei in blue. Scale bars: 10 mm. Error bars represent the SEM (n=3, *p<0.05, **p<0.01, ***p<0.001). + 
+ indicates the quantification limit.  
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